Drug Search Results
More Filters [+]

Efatutazone

Alternative Names: efatutazone
Latest Update: 2023-06-07
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PPAR-g Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Alliance for Clinical Trials in Oncology
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Efatutazone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Liposarcoma, Myxoid

Phase 1: Lymphoma|Multiple Myeloma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

A091202

P2

Completed

Liposarcoma, Myxoid

2018-10-04

NCT01504490

P1

Terminated

Multiple Myeloma|Lymphoma

2016-12-01

Recent News Events